Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
The Company has advanced well with its planned activities
- Closing the clinical and regulatory activities related to the CT001 program
- Organisational development, search for key competences
- Launch and supply planning with commercial partners
- US manufacturing technology transfer completed (in October Q4)
Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 1 July - 30 September 2025. The third quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.
Third quarter financial results 2025 (1 July - 30 September):
- Net Revenue was KDKK 1.243
- Operating result was KDKK -3.967
- Net result was KDKK -3.050
- Cash at bank end of the period was KDKK 9.090
- Earnings per share* was KDKK -0,16
- Solidity** was 84%
*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 30 September 2025 amounted to 18.576.437 shares, the average number of shares during the third quarter was 18.576.437
**Solidity: Total equity divided by total capital and liability
Comments from CEO, Jes Trygved:
"Building on our recent operational and regulatory progress, we have during third quarter closed the clinical activities for CT001 and completed the US manufacturing tech transfer in October (Q4). We are sharpening our organisational capabilities through a focused search for key competences, and we have initiated launch and supply planning with our commercial partners to support the next phase of CT001. Much of our efforts and current planning is still focused on upcoming US activities which will hopefully make a great impact. Thanks for a great effort by the team"